The global demand for Inhaled Nitric Oxide Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Nitric Oxide (NO) is an unsteady, odorless, and colorless water-soluble, free-radical gas. It reacts quickly with oxygen to form nitrogen oxides. NO is produced usually in several tissues, and it acts as a mediator in cell-to-cell communication. It plays a vital role in many biological processes, which include inflammation, vasodilatation, and neurotransmission. Inhaled nitric oxide (INO) is a pulmonary vasodilator that serves an essential function by regulating vascular muscle tone. INO was first approved by the Food and Drug Administration of the United States of America in 1999 for use as a medical gas. It is used to treat hypoxic respiratory failure related to clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Afterward, INO therapy is majorly used for treating PPHN in term and late preterm neonates. In adults, it is used for treating adult respiratory distress syndrome.
The major drivers strengthening the Inhaled Nitric Oxide Market includes growing respiratory disease such as acute respiratory distress syndrome (ARDS) across the globe. Also, increase in research and development investment in improving inhaled nitric oxide application in the healthcare sector will surely help in driving the demand of inhaled nitric oxide. Moreover, the high demand in the treatment for hypoxemic respiratory failure in newly born infants is positively impacting the market. It is highly effective in enhancing oxygenation in infants with continual pulmonary hypertension of the newborn (PPHN). Due to its selective pulmonary vasodilator effects, INO therapy is majorly used for treating hypoxemic respiratory failure in infants.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of inhaled nitric oxide.
The entire inhaled nitric oxide market has been sub-categorized into product type and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Product Type
- Neonatal Respiratory Treatment
- Asthma and COPD
- Acute Respiratory Distress Syndrome
- Malaria Treatment
- Tuberculosis Treatment
This section covers regional segmentation which accentuates on current and future demand for inhaled nitric oxide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Inhaled Nitric Oxide Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the inhaled nitric oxide market include Nu-Med Plus, Praxair Technology, Inc., Air Liquide Healthcare, Mallinckrodt, Merck KGaA. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.